How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
- By Product Type: Pancreatic Enzyme Replacement Therapy (PERT), Diagnostic Kits and Assays, Nutritional Supplements, Imaging Devices, Supportive Care Products
- By Therapeutic Approach: Enzyme Replacement Therapy, Nutritional Management, Symptomatic Treatment, Surgical Intervention Support
- By Diagnostic Method: Fecal Elastase Test, Direct Pancreatic Function Test, Imaging Techniques (MRI, CT, Ultrasound), Secretin Stimulation Test, 72-hour Fecal Fat Test
- By End User: Hospitals, Specialty Clinics, Diagnostic Laboratories, Home Healthcare Settings
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Sales
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pancreatic Enzyme Replacement Therapy (PERT) leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.180 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.188 →
Full report · locked preview
Everything inside the Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Therapeutic Approach 4
Diagnostic Method 5
End User 4
Distribution Channel 4
Companies profiled
AbbVie Inc.
Mylan N.V. (Viatris)
Nestlé Health Science
Digestive Care Inc.
Horizon Pharma plc
Takeda Pharmaceutical Company Limited
Fresenius Kabi AG
AstraZeneca plc
Boehringer Ingelheim GmbH
Pfizer Inc.
Sanofi S.A.
Abbott Laboratories
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Mylan N.V. (Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Nestlé Health Science
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Digestive Care Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Horizon Pharma plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Takeda Pharmaceutical Company Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Fresenius Kabi AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →AstraZeneca plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Boehringer Ingelheim GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Abbott Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Novartis AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Baxter International Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sandoz International GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,839M by 2033 · 4.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pancreatic Enzyme Replacement Therapy (PERT)42.1
- Diagnostic Kits and Assays11.6
- Nutritional Supplements16.9
- Imaging Devices18.6
- Supportive Care Products10.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,364M → $1,915M · 4.3%
Europe$950.8M → $1,313M · 4.1%
Asia Pacific$868.1M → $1,281M · 5.0%
Latin America$537.4M → $807.4M · 5.2%
Middle East and Africa$413.4M → $557.8M · 3.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.362026
4.382027
4.392028
4.402029
4.412030
4.422031
4.442032
4.452033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- AbbVie Inc.11.6
- Mylan N.V. (Viatris)22.8
- Nestlé Health Science6.8
- Digestive Care Inc.12.3
- Horizon Pharma plc7.3
- Takeda Pharmaceutical Company Limited11.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type22.8%
Therapeutic Approach24.8%
Diagnostic Method11.6%
End User27.0%
Distribution Channel13.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.6
- Europe22.4
- Asia Pacific21.8
- Latin America13.7
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | 98 | 84 | 95 | 83 | 91 | 79 | 88 |
| Mylan N.V. (Viatris) | 80 | 88 | 86 | 90 | 86 | 93 | 87 |
| Nestlé Health Science | 79 | 87 | 72 | 81 | 66 | 79 | 77 |
| Digestive Care Inc. | 79 | 68 | 81 | 63 | 73 | 68 | 72 |
| Horizon Pharma plc | 71 | 61 | 66 | 56 | 65 | 56 | 63 |
| Takeda Pharmaceutical Company Limited | 46 | 57 | 64 | 68 | 55 | 67 | 60 |
| Fresenius Kabi AG | 58 | 62 | 60 | 65 | 51 | 57 | 59 |
| AstraZeneca plc | 46 | 53 | 38 | 46 | 36 | 48 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- AbbVie Inc.
- Mylan N.V. (Viatris)
- Nestlé Health Science
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| AbbVie Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Mylan N.V. (Viatris) | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Nestlé Health Science | ◐ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Digestive Care Inc. | ✓ | ◐ | ✓ | ◐ | ◐ | − |
| Horizon Pharma plc | ✓ | ◐ | ◐ | ◐ | − | ◐ |
| Takeda Pharmaceutical Company Limited | ◐ | − | ✓ | ◐ | ◐ | ◐ |
| Fresenius Kabi AG | ◐ | ✓ | ◐ | ◐ | − | ◐ |
| AstraZeneca plc | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1AbbVie Inc.88
2Mylan N.V. (Viatris)87
3Nestlé Health Science77
4Digestive Care Inc.72
5Horizon Pharma plc63
6Takeda Pharmaceutical Company Limited60
7Fresenius Kabi AG59
8AstraZeneca plc45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
AbbVie Inc.Mylan N.V. (Viatris)
Challenger2
Strong scale, closing on the leaders.
Nestlé Health ScienceDigestive Care Inc.
Contender3
Focused players with pockets of strength.
Horizon Pharma plcTakeda Pharmaceutical Company LimitedFresenius Kabi AG
Niche1
Specialists in a single segment or region.
AstraZeneca plc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market — a $558M beachhead inside a $7.89B market.
Beachhead (SOM)$558Mobtainable near-term
Serviceable (SAM)$3.03Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Pancreatic Enzyme Replacement Therapy (PERT)
Best fit — highest urgency & budget in Product Type.
Economic buyer81 fit
Diagnostic Kits and Assays
Strong fit — clear ROI and a fast path to value.
End user67 fit
Nutritional Supplements
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Approach & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Diagnostic Method
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel30%
Digital / self-serve17%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified22%
Evaluation14%
Closed-won5%
$21.2KCAC
$73KLTV
3.4:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market is a high-growth opportunity — $8.10B by 2033, compounding at 10.9%.
TAM · 2025$3.54Btoday
TAM · 2033$8.10Bforecast
CAGR10.9%2027–2033
Cumulative$49.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.10BTotal addressable market
SAM$2.87BServiceable available market
SOM$610MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.9% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.10BLarge & growingTAM by 2033 at 10.9% CAGR
$2.87BServiceable nowreachable with today’s model
$610MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.32BBear7.1% CAGR
$8.10BBase10.9% CAGR
$10.4BBull14.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Approach optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market — a $7.65B market by 2033. Plan: grow share from 6.4% to 12.0%.
Market size · 2033$7.65Btotal addressable
Market CAGR5.3%2027–2033
Target share12.0%from 6.4% today
Revenue ambition$918Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.4% | 12.0% | At risk |
| Revenue | $501M | $918M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 31.6% | 41.3% | At risk |
| Customer retention | 90.0% | 93.1% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Approach capability
A defensible second engine — invest in Therapeutic Approach to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Approach
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $134M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Approach
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market conversation — a $6.36B market you can size, segment and defend in minutes.
Market size · 2033$6.36Btotal opportunity
Growth7.9%CAGR to 2033
Addressable buyers1,655+accounts in scope
Typical ROI7.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.2×return on cost, year one
< 4 mopayback period
$74K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
AbbVie Inc.Mylan N.V. (Viatris)Nestlé Health ScienceDigestive Care Inc.Horizon Pharma plcTakeda Pharmaceutical Company LimitedFresenius Kabi AGAstraZeneca plc+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Extracorporeal CO2 Removal Market
Market size, share, segmentation and regional forecast.
$602M market · 2025 base year
View reportExtracorporeal Membrane Oxygenation Machine Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportFluid Management Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportFragment-based Drug Discovery Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportGeneric Injectables Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportGenetic Testing Services Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportGenomics And Proteomics Reagents, Research Kits and Analytical Instruments Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportGenomics Personalized Health Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportHematological Malignancies Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportHemoglobin A1c Testing Devices Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportHemophilia Treatment Drugs Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportHemostasis Diagnostics Market
Market size, share, segmentation and regional forecast.
$955M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.